825619-29-2

Basic information

• Product Name: 1H-BenziMidazole, 6-(4-MorpholinylMethyl)-2-(4-nitro-1H-pyrazol-3-yl)-
• Synonyms: 1H-BenziMidazole, 6-(4-MorpholinylMethyl)-2-(4-nitro-1H-pyrazol-3-yl)-;4-((2-(4-nitro-1H-pyrazol-3-yl)-1H-benzo[d]imidazol-5-yl)methyl)morpholine
• CAS NO: 825619-29-2
• Molecular Formula: C15H16N6O3
• Molecular Weight: 328.32594
• Mol File: 825619-29-2.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-BenziMidazole, 6-(4-MorpholinylMethyl)-2-(4-nitro-1H-pyrazol-3-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-BenziMidazole, 6-(4-MorpholinylMethyl)-2-(4-nitro-1H-pyrazol-3-yl)-(825619-29-2)
• EPA Substance Registry System: 1H-BenziMidazole, 6-(4-MorpholinylMethyl)-2-(4-nitro-1H-pyrazol-3-yl)-(825619-29-2)

Safety Data

• Hazardous Substances Data: 825619-29-2(Hazardous Substances Data)

Usage

Synonym

JAK2 inhibitor II

Chemical Class

Benzimidazole derivative

Target Enzyme

Janus kinase 2 (JAK2)

Role

Inhibits JAK2, an enzyme involved in cell growth and proliferation signaling pathways

Potential Applications

Therapeutic agent for the treatment of various diseases, including cancer and inflammatory disorders

Unique Chemical Structure

Includes a morpholine and nitro-pyrazole moiety

Value in Research

Valuable compound for further research and development in medicinal chemistry.

Upstream product

• 825619-02-1 4-morpholin-4-ylmethylbenzene-1,2-diamine 
• 5334-40-7 4-nitro-1H-pyrazole-3-carboxylic acid 
• 825619-03-2 4-(3,4-dinitrobenzyl)-morpholine 
• 528-45-0 3,4-dinitrobenzoic acid 
• 24376-18-9 3,4-dinitrobenzoyl chloride 
• 65003-28-3 (3,4-dinitrophenyl)(morpholin-4-yl)methanone 

Downstream Products

• 1254229-30-5 N-{4-[4-chloro-6-({3-[5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl]-1H-pyrazol-4-yl}amino)pyrimidin-2-ylthio]phenyl}cyclopropanecarboxamide 

Relevant articles and documents

Pyrazole spleen tyrosine kinase inhibitor as well as preparation method and application thereof

The invention discloses a pyrazole spleen tyrosine kinase inhibitor, a preparation method thereof, a pharmaceutical composition containing the same, and application of the pyrazole spleen tyrosine kinase inhibitor and the pharmaceutical composition in the preparation of drugs for treating Syk-mediated diseases including cancers, inflammatory diseases and the like.

As Aurora kinase inhibitor derivatives

The present invention relates to a substituted pyrazole derivative used for inhibiting Aurora kinase and represented by formula (I) or formula (Ia), or stereo isomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, esters, pharmaceutically acceptable salts or prodrugs thereof, a medicinal composition containing the above compounds as active ingredients, and a use of the compounds and the medicinal composition in preparation of medicines for protecting, processing, treating or mitigating proliferative diseases of patients.

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity

Here, we describe the identification of a clinical candidate via structure-based optimization of a ligand efficient pyrazole-benzimidazole fragment. Aurora kinases play a key role in the regulation of mitosis and in recent years have become attractive tar